Appili Therapeutics Inc News

Express News | Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials

ReutersDec 12 08:15 ET

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement With Aditxt, Inc.

GlobeNewswireNov 19 07:17 ET

Appili Therapeutics Inc: INTERIM MDA EN

SEDARNov 14 08:27 ET · Announcements

Appili Therapeutics Inc: INTERIM FINANCIAL STATEMENTSREPORT EN

SEDARNov 14 08:27 ET · Announcements

Express News | Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

ReutersNov 14 07:15 ET

Express News | Aditxt Provides Update on Equity Line of Credit, Atm Usage, and Outstanding Number of Shares

ReutersNov 8 08:31 ET

Express News | Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger With Aditxt's Subsidiary Adifem

ReutersNov 6 08:30 ET

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment With FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

BusinesswireOct 31 08:30 ET

Appili Therapeutics Announces "Alignment" With FDA on ATI-1801 Development Requirements

MT NewswiresOct 31 07:57 ET

Express News | Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership With Broader Perspectives

ReutersOct 29 08:15 ET

Appili Therapeutics – Press Release Correction

GlobeNewswireOct 10 15:40 ET

Express News | Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

ReutersOct 10 08:15 ET

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

GlobeNewswireSep 17 17:11 ET

Appili Therapeutics Brief: Says Definitive Agreement With Aditxt, If Approved by Appili Shareholders, "Provides Significant Premium to Shareholders and Resources to Advance Key Programs"

MT NewswiresAug 13 17:30 ET

Appili Therapeutics Brief: Notes U.S. Food and Drug Administration Meeting Request Submitted to Discuss ATI-1801 Registration Strategy

MT NewswiresAug 13 17:28 ET

Express News | Aditxt Inc - Transaction Is Conditional Upon Aditxt Raising at Least US$20 Mln in Financing Before Closing

ReutersJul 25 08:31 ET

Aditxt Signs Second Amendment to the Arrangement Agreement With Appili Therapeutics, Targeting September 30 Closing of the Acquisition

Stockhouse Jul 25 08:30 ET

Appili Therapeutics Q4 Loss Narrows Amid Increase in Government Assistance

MT NewswiresJun 26 06:31 ET

Appili Therapeutics Inc: MDA EN

SEDARJun 25 22:05 ET · Announcements

Appili Therapeutics Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN

SEDARJun 25 21:58 ET · Announcements